TY - JOUR
T1 - Comprehensive analysis platform to understand, remedy, and eliminate amyotrophic lateral sclerosis (CAPTURE ALS)
T2 - Study protocol for a Canadian multicenter, multimodal, longitudinal observational study
AU - Saunders, Natalie
AU - Magnussen, Claire
AU - Kang, Hyung Mo
AU - Blais, Mathieu
AU - Bhinder, Harpreet
AU - Pfeffer, Gerald
AU - Genuis, Shelagh K.
AU - Bouvier, Liziane
AU - Anand, Tanushka
AU - Abou-Haidar, Rida
AU - Abrahao, Agessandro
AU - Boivin, Marie Noëlle
AU - Bowser, Robert
AU - Bubela, Tania
AU - Chiappini, Julia
AU - Das, Samir
AU - Dhanoa, Avnit
AU - Dupré, Nicolas
AU - Evans, Alan
AU - Ferry, Nicolas
AU - Frater, Yvonne
AU - Genge, Angela
AU - Graham, Simon J.
AU - Greiner, Russell
AU - Medina, Yasser Iturria
AU - Johnston, Wendy S.
AU - Jones, Kelvin E.
AU - Karamchandani, Jason
AU - Kriz, Jasna
AU - Luth, Westerly
AU - Matte, Geneviève
AU - Rogaeva, Ekaterina
AU - Robertson, Janice
AU - Seres, Peter
AU - Tam, Fred
AU - Taylor, David
AU - Tremblay-Desbiens, Clémence
AU - Velde, Christine Vande
AU - Yunusova, Yana
AU - Zinman, Lorne
AU - Kalra, Sanjay
N1 - Publisher Copyright:
© 2025 Saunders et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2025/12
Y1 - 2025/12
N2 - Background The marked heterogeneity of Amyotrophic Lateral Sclerosis (ALS) combined with a lack of biomarkers are key contributing factors to the lack of disease-modifying treatments. The Comprehensive Analysis Platform to Understand Remedy and Eliminate ALS (CAPTURE ALS) is a Canadian platform designed to create the most comprehensive picture of people living with ALS with the objective of facilitating ALS research initiatives worldwide. Objectives The main aims of CAPTURE ALS include: (1) to characterize ALS and healthy controls with biosamples and data in order to provide the most comprehensive picture of individuals living with ALS to date; (2) to create a de-identified database and biosample repository linked to detailed clinical information; and (3) to develop and implement an inclusive and transparent participant engagement strategy to be active throughout all stages of CAPTURE ALS. Methods/Results CAPTURE ALS is a prospective, multicenter, observational, longitudinal study. People living with ALS, or a related disease and healthy controls undergo a harmonized protocol including the collection of detailed clinical information, neurological and cognitive examination, speech recording, advanced magnetic resonance imaging, and biosampling. Data and samples are stored in a biobank operating under an open science governance framework. An inclusive and transparent participant engagement strategy was designed and implemented throughout all stages of CAPTURE ALS. Four sites are operating in the consortium with a fifth being onboarded. The target enrollment is 120 affected participants and 50 controls, with the first participant visit having occurred in March 2022. Recruitment is ongoing. Discussion CAPTURE ALS is a scalable clinical research platform that connects scientists and patients to facilitate efficient translational research. The unique and deeply phenotyped data and biosamples are a global resource towards the development of biomarkers and understanding ALS biology.
AB - Background The marked heterogeneity of Amyotrophic Lateral Sclerosis (ALS) combined with a lack of biomarkers are key contributing factors to the lack of disease-modifying treatments. The Comprehensive Analysis Platform to Understand Remedy and Eliminate ALS (CAPTURE ALS) is a Canadian platform designed to create the most comprehensive picture of people living with ALS with the objective of facilitating ALS research initiatives worldwide. Objectives The main aims of CAPTURE ALS include: (1) to characterize ALS and healthy controls with biosamples and data in order to provide the most comprehensive picture of individuals living with ALS to date; (2) to create a de-identified database and biosample repository linked to detailed clinical information; and (3) to develop and implement an inclusive and transparent participant engagement strategy to be active throughout all stages of CAPTURE ALS. Methods/Results CAPTURE ALS is a prospective, multicenter, observational, longitudinal study. People living with ALS, or a related disease and healthy controls undergo a harmonized protocol including the collection of detailed clinical information, neurological and cognitive examination, speech recording, advanced magnetic resonance imaging, and biosampling. Data and samples are stored in a biobank operating under an open science governance framework. An inclusive and transparent participant engagement strategy was designed and implemented throughout all stages of CAPTURE ALS. Four sites are operating in the consortium with a fifth being onboarded. The target enrollment is 120 affected participants and 50 controls, with the first participant visit having occurred in March 2022. Recruitment is ongoing. Discussion CAPTURE ALS is a scalable clinical research platform that connects scientists and patients to facilitate efficient translational research. The unique and deeply phenotyped data and biosamples are a global resource towards the development of biomarkers and understanding ALS biology.
UR - https://www.scopus.com/pages/publications/105023912780
U2 - 10.1371/journal.pone.0332430
DO - 10.1371/journal.pone.0332430
M3 - Article
C2 - 41343582
AN - SCOPUS:105023912780
SN - 1932-6203
VL - 20
JO - PLoS ONE
JF - PLoS ONE
IS - 12 December
M1 - e0332430
ER -